Publications by authors named "Daniel Vitt"

Claim this Profile
S
Selective disruption of RORγt-CBFβ interaction by IMU-935 prevents RORγt-dependent Th17 autoimmunity but not thymocyte development.
Hongmin Wu, Xiancai Zhong, Ning Ma, Zhiheng He, Guanpeng Wang, Daniel Vitt

J Clin Invest· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity.
Tanja Stiller, Christian Gege, Wael Saeb, Jan Vietor, Úrsula López-García, Daniel Vitt

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.
Geert D'Haens, Kalina Grivcheva Stardelova, Edite Sadiku, Natallia Kizlova, Syitlana Skybalo, Daniel Vitt

Clin Transl Gastroenterol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
A James M Daveson, Richard Stubbs, Thomas M Polasek, Jorma Isola, Robert Anderson, Daniel Vitt

Lancet Gastroenterol Hepatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.
Alexandra Herrmann, Christian Gege, Christina Wangen, Sabrina Wagner, Melanie Kögler, Daniel Vitt

Antiviral Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity.
Christian Gege, Friedrich Hahn, Christina Wangen, Sigrun Häge, Alexandra Herrmann, Daniel Vitt

ChemMedChem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.
Robert J Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Daniel Vitt

Neurol Neuroimmunol Neuroinflamm· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.
Christina Wangen, Andrea Raithel, Julia Tillmanns, Christian Gege, Alexandra Herrmann, Daniel Vitt

Antiviral Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Thomas M Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Daniel Vitt

Clin Pharmacol Drug Dev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Maria J G T Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Daniel Vitt

Infect Dis Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators.
Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Daniel Vitt

ACS Chem Biol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
Kim M Stegmann, Antje Dickmanns, Natalie Heinen, Claudia Blaurock, Tim Karrasch, Daniel Vitt

iScience· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Daniel Vitt

Viruses· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases.
Andreas Muehler, Jason R Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt

World J Gastrointest Pathophysiol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt

Eur J Drug Metab Pharmacokinet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt

Mult Scler Relat Disord· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H Kuhn, Daniel Vitt

Viruses· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt

Drugs R D· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Wolfgang Gruber, Elisabeth Peer, Dominik P Elmer, Christina Sternberg, Suzana Tesanovic, Daniel Vitt

Int J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.
Corina Hutterer, Jens Milbradt, Stuart Hamilton, Mirko Zaja, Johann Leban, Daniel Vitt

Antiviral Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Wolfgang Gruber, Martin Hutzinger, Dominik Patrick Elmer, Thomas Parigger, Christina Sternberg, Daniel Vitt

Oncotarget· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients.
Julia Richter, Kalim Ullah, Pengfei Xu, Vanessa Alscher, Annette Blatz, Daniel Vitt

Int J Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1δ and ε with nanomolar inhibitory activity on cancer cell proliferation.
Julia Richter, Joachim Bischof, Mirko Zaja, Hella Kohlhof, Olaf Othersen, Daniel Vitt

J Med Chem· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.
Manfred Marschall, Ina Niemann, Karin Kosulin, Anna Bootz, Sabrina Wagner, Daniel Vitt

Antiviral Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.
Emanuel Haasbach, Sarah Julia Reiling, Christina Ehrhardt, Karoline Droebner, Andrea Rückle, Daniel Vitt

Antiviral Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis